Physician profile
Priscilla Jean Benner
NPI 1629078936
$3,127.71
in general payments reported to CMS, 2019-2025
29 companies · $68.63 in 2025
The $68.63 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $500 · 2021: $768 · 2022: $806 · 2023: $454 · 2024: $172 · 2025: $68.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $724.14 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $333.94 | 2019-2022 | |
| Allergan, INC. | $249.51 | 2019-2020 | |
| Lilly USA, LLC | $237.22 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $169.06 | 2019-2023 | Breztri, Fasenra |
| Sunovion Pharmaceuticals INC. | $143.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $132.74 | 2019-2022 | |
| Astellas Pharma US INC | $126.93 | 2019-2023 | Veozah |
| Amgen INC. | $119.34 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $95.22 | 2021-2023 | Keveyis |
| Pfizer INC. | $86.14 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.14 | 2022 | |
| Merck Sharp & Dohme LLC | $71.51 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.80 | 2020-2023 | Jardiance |
| Gilead Sciences, INC. | $64.73 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $53.81 | 2021-2022 | |
| Exact Sciences Corporation | $53.55 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $47.49 | 2021-2022 | |
| Glaxosmithkline, LLC. | $44.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.20 | 2019-2024 | |
| Bausch Health US, LLC | $33.57 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $30.61 | 2021 | |
| Alexion Pharmaceuticals, INC. | $30.00 | 2021 | |
| Almatica Pharma LLC | $19.00 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.72 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.92 | 2023 | Xifaxan |
| Linus Health, INC. | $16.76 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $16.28 | 2022 | |
| Acadia Pharmaceuticals INC | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priscilla Benner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.